# Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

> **NCT01744782** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 17 (actual)

## Conditions studied

- Cystinosis

## Interventions

- **DRUG:** RP103

## Key facts

- **NCT ID:** NCT01744782
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-20
- **Primary completion:** 2016-12-13
- **Final completion:** 2016-12-13
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01744782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01744782, "Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01744782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*